Key result
Adjuvant capecitabine chemotherapy linked to rare acute aortic thrombosis in a single patient.
Why the study?
Acute aortic thrombosis is an extremely rare complication in patients receiving chemotherapy despite the known elevated risk for thromboembolic events in cancer patients.
Case Report (n=1)
Highlights acute aortic thrombosis as an extremely rare but severe cardiovascular complication of capecitabine chemotherapy in cancer patients.
Capecitabine may rarely cause acute aortic thrombosis; this case leaves open causality and should not change practice.
The elevated risk for thromboembolic events in cancer patients has been well documented. Chemotherapy is considered to be one of the most important risk factors for cardiovascular complications such as arrhythmias, cardiomyopathy, angina, and myocardial infarction. However, acute aortic thrombosis is an extremely rare complication in patients receiving chemotherapy. The authors report a case of acute aortic thrombosis after adjuvant capecitabine chemotherapy for colon cancer.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2018) conducted a case report in Colon cancer (n=1). Capecitabine chemotherapy was evaluated on Acute aortic thrombosis. Adjuvant capecitabine chemotherapy for colon cancer was associated with the rare complication of acute aortic thrombosis in a single patient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: